Northern Trust
ACRV icon

Northern Trust’s Acrivon Therapeutics ACRV Stock Holding History

Northern Trust’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$120K Buy
67,202
+18,300
+37% +$31.1K ﹤0.01% 4083
2026
Q1 		$68K Sell
48,902
-14,816
-23% -$25.8K ﹤0.01% 4189
2025
Q4 		$154K Buy
63,718
+21,552
+51% +$46.8K ﹤0.01% 4052
2025
Q3 		$76.3K Sell
42,166
-4,610
-10% -$6.48K ﹤0.01% 4196
2025
Q2 		$55.7K Sell
46,776
-62,249
-57% -$85.4K ﹤0.01% 4212
2025
Q1 		$221K Sell
109,025
-8,298
-7% -$44.7K ﹤0.01% 3910
2024
Q4 		$706K Buy
117,323
+11,925
+11% +$86.7K ﹤0.01% 3532
2024
Q3 		$738K Sell
105,398
-8,655
-8% -$68.2K ﹤0.01% 3455
2024
Q2 		$662K Buy
114,053
+6,303
+6% +$50.8K ﹤0.01% 3402
2024
Q1 		$770K Buy
107,750
+27,601
+34% +$128K ﹤0.01% 3412
2023
Q4 		$394K Buy
80,149
+7,427
+10% +$39.2K ﹤0.01% 3622
2023
Q3 		$695K Buy
72,722
+4,044
+6% +$46.7K ﹤0.01% 3415
2023
Q2 		$890K Sell
68,678
-1,073
-2% -$13K ﹤0.01% 3400
2023
Q1 		$885K Buy
+69,751
New +$1.17M ﹤0.01% 3260

Other funds holding ACRV

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Sands Capital Ventures
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Bridgeway Capital Management
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust's ACRV Position: Q2 2026 in Review

Northern Trust increased its Acrivon Therapeutics (ACRV) stake by 37% in Q2 2026, buying an estimated $31.1K and bringing the position to 67,202 shares worth $120K. The position accounts for ﹤0.01% of the portfolio, ranked #4083.

Northern Trust first reported a position in ACRV in Q1 2023 and has held it in 14 quarters since. The position peaked at $890K in Q2 2023. 46 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

  • Northern Trust held 67,202 shares of Acrivon Therapeutics worth $120K as of Q2 2026.
  • Northern Trust bought 18,300 Acrivon Therapeutics shares in Q2 2026, an estimated $31.1K.
  • Acrivon Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #4083 holding.
  • Northern Trust first reported a position in Acrivon Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Northern Trust's Acrivon Therapeutics position peaked at $890K in Q2 2023.
  • 46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.